Business Wire

Midea VRF Going Global, Sets Sail for Jakarta-Bandung High-speed Railway

Share

The G20 Bali Summit presented the latest construction results of the Jakarta-Bandung High-speed Railway (HSR), the first high-speed railway in Southeast Asia. With a total length of 142 kilometers and a maximum design speed of 350 kilometers per hour, marking that Indonesia has entered the "high-speed rail era". Midea provides professional HVAC solutions and the most intimate services and sends "Midea Coolness" for Jakarta-Bandung HSR with 126 ODUs and 705 IDUs of Midea VC Pro.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115006013/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Midea VC Pro VRFs have been used in Jakarta-Bandung High-Speed Railway (HSR), Dubai Expo and many other overseas projects. (Graphic: Business Wire)

The HVAC project is vital equipment support for Jakarta-Bandung HSR. Jakarta-Bandung Railway is located in the tropical rainforest climate zone of Java Island and is influenced by the equatorial climate. The operator of the HSR needs a reliable and stable central air conditioning system to adapt to the high temperature and high humidity working conditions without downtime and effectively maintain the constant temperature of the HSR building space.

With a leading position in the global HVAC industry, Midea Building Technologies provides Jakarta-Bandung HSR professional air conditioning solutions. The multi-fluid chip liquid cooling technology can cool the electric control parts in time, and about 8 degrees can reduce the average temperature of the electric control parts, which can maintain strong cooling in high-temperature environments. In terms of corrosion resistance, the VC Pro VRFs ODUs can still operate stably under the severe corrosion of salt pollution environment by simulating experimental tests.

Besides facing the problems of a large construction area and high population flow in the HSR station, Site 4, which Midea MBT won the bid for, containing six building types such as station buildings, apartment buildings, etc., is the most complex site for the installation of central air conditioning for the Jakarta-Bandung HSR. Moreover, in Indonesia, the procurement of installation materials for the project was restricted in many ways. All aspects had to be evaluated in the process of selection. The air conditioning design plan was also updated again and again and refined over and over again. Finally, the optimal quality and efficiency of the HVAC installation project were achieved with the combination of multi-type design and multi-layout form.

Midea VC Pro VRFs have also been used in Dubai Expo and many other overseas projects. Now, Midea Building Technologies has localized its sales and service networks in the international market, forming a comprehensive layout from core technology, and original products to differentiated customized solutions.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lori Luo
+86 13512784739
luory17@midea.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 12:15:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Cardiology (ESC) Congress 2025 held in Madrid, Spain. These data reflect outcomes of treatment through up to 48 months, including the initial double-blind period of 33-36 months, and highlight the ongoing clinical benefit of vutrisiran, which causes rapid knockdown of the disease-causing transthyretin (TTR) protein, including a 37% risk reduction in the composite endpoint of all-cause mortality (ACM) or first cardiovascular (CV) event in the overall population (p<0.001) and a 42% risk reduction in th

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 09:30:00 EEST | Press release

Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial intelligence and digital transformation. “WETEX reflects the UAE's unwa

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 19:00:00 EEST | Press release

Daiichi Sankyo Europe is pleased to announce the initiation of the development of new oral triple combination tablets in Europe of bempedoic acid, ezetimibe, and different doses of a statin (atorvastatin or rosuvastatin), with the potential to lower low-density lipoprotein cholesterol (LDL-C) levels.9 It is well known that combination therapies reduce the pill burden for patients, potentially enhancing treatment adherence and facilitating treatment with a goal of improving cardiovascular outcomes.9,10 “As bempedoic acid and ezetimibe are already approved as a single-dose therapy, the development of an oral triple combination tablet with different doses of a statin, can make it easier for physicians to tailor treatment to the individual needs of each patient,” says Dr. Stefan Seyfried, Vice President and Head Medical Affairs Specialty Medicines, Daiichi Sankyo Europe. “This approach exemplifies our dedication to our motto: ‘we care for every heartbeat’.” “The management of dyslipidaemia

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 17:30:00 EEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from the comprehensive KARDIA Phase 2 program, including KARDIA-3 results presented today as a late-breaking abstract at the European Society of Cardiology (ESC) Congress in Madrid, Spain. Zilebesiran is an investigational subcutaneously administered RNAi therapeutic which, in the KARDIA Phase 2 program, has shown reductions in blood pressure by targeting liver-expressed angiotensinogen (AGT), the most upstream precursor in the Renin-Angiotensin-Aldosterone System (RAAS), which plays a key role in blood pressure regulation and impacts cardiovascular and renal health. KARDIA-3, the third Phase 2 study in the KARDIA program, evaluated the efficacy and safety of zilebesiran in patients with

BeOne Medicines Announces Positive Topline Results for Sonrotoclax in Relapsed or Refractory Mantle Cell Lymphoma (MCL)29.8.2025 13:00:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced positive topline results from a Phase 1/2 study (BGB-11417-201) of sonrotoclax, a next-generation and potentially best-in-class investigational BCL2 inhibitor, in adult patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), following treatment with a Bruton’s tyrosine kinase inhibitor (BTKi) and anti-CD20 therapy. BeOne plans to present the full data at an upcoming medical meeting. “For people with relapsed or refractory mantle cell lymphoma, the disease is aggressive, the treatment landscape fragmented, and the outcomes unacceptably poor. These topline results for sonrotoclax underscore its potential to deliver meaningful and durable responses and offer the first BCL2 inhibitor for patients with R/R MCL, if approved,” said Lai Wang, PhD, Global Head of R&D, BeOne Medicines. “These data add to the remarkable progress we’ve seen over the past five years in treating B-cel

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye